Genzyme Corporation

Markus Metz

John L Kane, Jr

Andrew Scholte

Michael Kothe

Jinyu Liu

Gloria Matthews

Renato Skerlj

Elyse Bourque

Gary James Bridger

Yuanxi Zhou

Tong-Shuang Li

Wen Yang

Jonathan Langille

Seng H Cheng

Andrew Charles Good

Ernest John McEachern

David Earl Bogucki

Curtis Harwig

John Marshall

Yibin Xiang

Bradford Hirth

Cassandra Celatka

Yongbao Zhu

Ronald K Scheule

Zhong Zhao

Mark Czekaj

Thomas A Natoli

Ian R Baird

Liang Ma

Elina Makino

Oxana Beskrovnaya

Herve Husson

Claude Barberis

Barret Giese

Tieu-Binh Le

Linli Wei

Katherine Jancsics

Vinod Francis Patel

Dominique Schols

Al Kaller

Siqiao Nan

John P Leonard

John L Kane

Paul Erdman

Mario A Cabrera-Salazar

Maria Rosaria Di Fluri

Gang Chen

Renato Tony Skerlj

Krystyna Skupinska

Patrick Wai-Kwok Shum

John Leonard

Patrick Shum

Katherine Jancisics

Ronald Scheule

Mario Cabrera-Salazar

Compounds of the formula or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. The compounds are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Colony stimulating factor-1 receptor (CSF-1R) inhibitors

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Tropomyosin-related kinase (trk) inhibitors

The invention relates to inhibitors of glucosylceramide synthase (GCS) of the Formula I: represented by the following structural formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

Glucosylceramide synthase inhibitors

Tropomyosin-related kinase (Trk) inhibitors

Tropomyosin-related kinase (TRK) inhibitors

Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. 

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Chemokine receptor binding compounds

Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Growing community of inventors

Encinitas, CA, United States of America

Markus Metz